Vanguard Group Inc. Grows Holdings in Kodiak Sciences Inc. $KOD

Vanguard Group Inc. grew its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 18.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,313,395 shares of the company’s stock after purchasing an additional 363,103 shares during the period. Vanguard Group Inc. owned about 4.36% of Kodiak Sciences worth $64,683,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new stake in Kodiak Sciences in the fourth quarter worth $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kodiak Sciences in the fourth quarter worth $72,000. BNP Paribas Financial Markets increased its stake in Kodiak Sciences by 89.4% in the third quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock worth $104,000 after purchasing an additional 3,009 shares during the period. American Century Companies Inc. increased its stake in Kodiak Sciences by 6.3% in the second quarter. American Century Companies Inc. now owns 79,745 shares of the company’s stock worth $297,000 after purchasing an additional 4,703 shares during the period. Finally, Headlands Technologies LLC increased its stake in Kodiak Sciences by 256.4% in the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock worth $30,000 after purchasing an additional 5,815 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Kodiak Sciences Stock Performance

NASDAQ KOD opened at $38.70 on Friday. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of -9.28 and a beta of 2.32. The company’s 50-day simple moving average is $36.21 and its two-hundred day simple moving average is $28.37. Kodiak Sciences Inc. has a one year low of $2.81 and a one year high of $47.84.

Kodiak Sciences (NASDAQ:KOD) last posted its earnings results on Thursday, May 7th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.01). Equities analysts expect that Kodiak Sciences Inc. will post -3.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on KOD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $14.00 to $61.00 in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Finally, UBS Group increased their target price on Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.14.

Kodiak Sciences Profile

Kodiak Sciences, Inc is a clinical?stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.